ZIIHERA DIN 02564610
Health Canada record
| Active ingredient(s) | ZANIDATAMAB 300 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FD07 ZANIDATAMAB |
| Original market date | |
| Current status date | 15-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jazz Pharmaceuticals Canada Inc. — licence 3-002453, currently licensed, last inspection rating C (2024-12-02).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36774 | 2026-01-15 | New Drug Submission (NDS) |